Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Net Income towards Common Stockholders: 2018-2022

Historic Net Income towards Common Stockholders for ADC Therapeutics (ADCT) over the last 5 years, with Dec 2022 value amounting to -$155,800.

  • ADC Therapeutics' Net Income towards Common Stockholders fell 189.52% to -$45.3 million in Q3 2023 from the same period last year, while for Sep 2023 it was -$153.5 million, marking a year-over-year decrease of 216.62%. This contributed to the annual value of -$155,800 for FY2022, which is 32.27% up from last year.
  • According to the latest figures from FY2022, ADC Therapeutics' Net Income towards Common Stockholders is -$155,800, which was up 32.27% from -$230,026 recorded in FY2021.
  • ADC Therapeutics' Net Income towards Common Stockholders' 5-year high stood at -$116,484 during FY2019, with a 5-year trough of -$246,290 in FY2020.
  • In the last 3 years, ADC Therapeutics' Net Income towards Common Stockholders had a median value of -$230,026 in 2021 and averaged -$210,705.
  • Per our database at Business Quant, ADC Therapeutics' Net Income towards Common Stockholders plummeted by 111.44% in 2020 and then surged by 32.27% in 2022.
  • Yearly analysis of 5 years shows ADC Therapeutics' Net Income towards Common Stockholders stood at -$123,096 in 2018, then grew by 5.37% to -$116,484 in 2019, then slumped by 111.44% to -$246,290 in 2020, then rose by 6.60% to -$230,026 in 2021, then soared by 32.27% to -$155,800 in 2022.